User login
Key clinical point: The preadmission antidiabetic medications may influence mortality outcomes in patients with COVID-19 and type 2 diabetes (T2D).
Major finding: The risk for in-hospital mortality was significantly lower among patients taking metformin (odd ratio [OR] 0.54; 95% CI 0.47-0.62), glucagon-like peptide-1 receptor agonist (OR 0.51; 95% CI 0.37-0.69), and sodium-glucose transporter-2 inhibitor (OR 0.60; 95% CI 0.40-0.88), but higher among those taking dipeptidyl peptidase-4 inhibitor (OR 1.23; 95% CI 1.07-1.42) and insulin (OR 1.70; 95% CI 1.33-2.19), compared with patients taking none of these medications. Sulfonylurea, thiazolidinedione, and alpha-glucosidase inhibitors showed neutral effects on mortality.
Study details: The data come from a meta-analysis of 61 studies including 3,061,584 patients with COVID-19 and T2D.
Disclosures: This study received no specific grant from any funding agency.
Source: Nguyen NN et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131:155196 (Mar 31). Doi: 10.1016/j.metabol.2022.155196
Key clinical point: The preadmission antidiabetic medications may influence mortality outcomes in patients with COVID-19 and type 2 diabetes (T2D).
Major finding: The risk for in-hospital mortality was significantly lower among patients taking metformin (odd ratio [OR] 0.54; 95% CI 0.47-0.62), glucagon-like peptide-1 receptor agonist (OR 0.51; 95% CI 0.37-0.69), and sodium-glucose transporter-2 inhibitor (OR 0.60; 95% CI 0.40-0.88), but higher among those taking dipeptidyl peptidase-4 inhibitor (OR 1.23; 95% CI 1.07-1.42) and insulin (OR 1.70; 95% CI 1.33-2.19), compared with patients taking none of these medications. Sulfonylurea, thiazolidinedione, and alpha-glucosidase inhibitors showed neutral effects on mortality.
Study details: The data come from a meta-analysis of 61 studies including 3,061,584 patients with COVID-19 and T2D.
Disclosures: This study received no specific grant from any funding agency.
Source: Nguyen NN et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131:155196 (Mar 31). Doi: 10.1016/j.metabol.2022.155196
Key clinical point: The preadmission antidiabetic medications may influence mortality outcomes in patients with COVID-19 and type 2 diabetes (T2D).
Major finding: The risk for in-hospital mortality was significantly lower among patients taking metformin (odd ratio [OR] 0.54; 95% CI 0.47-0.62), glucagon-like peptide-1 receptor agonist (OR 0.51; 95% CI 0.37-0.69), and sodium-glucose transporter-2 inhibitor (OR 0.60; 95% CI 0.40-0.88), but higher among those taking dipeptidyl peptidase-4 inhibitor (OR 1.23; 95% CI 1.07-1.42) and insulin (OR 1.70; 95% CI 1.33-2.19), compared with patients taking none of these medications. Sulfonylurea, thiazolidinedione, and alpha-glucosidase inhibitors showed neutral effects on mortality.
Study details: The data come from a meta-analysis of 61 studies including 3,061,584 patients with COVID-19 and T2D.
Disclosures: This study received no specific grant from any funding agency.
Source: Nguyen NN et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism. 2022;131:155196 (Mar 31). Doi: 10.1016/j.metabol.2022.155196